Advertisement

Lung Cancer

  • Solange Peters
  • Stefan Zimmermann
Chapter

Abstract

Systemic therapy of lung cancer relies on an accurate staging of the disease, identification of key predictive tumor-related biomarkers, but also on careful evaluation of patient characteristics, including capability of tolerating each specific treatment strategy as well as patient’s preferences. Therefore, a solid knowledge on all intervention-related adverse events and drug toxicities is essential for an optimal decision-making process.

The majority of lung cancer patients are diagnosed at an advanced, metastatic, stage of the disease, correlated with a dismal prognosis. Systemic palliative therapy remains the mainstay.

This chapter describes the standard drug options and their respective toxicities. Side effects of more complex multimodality treatments of early non-small cell lung cancer (NSCLC) as well as small-cell lung cancer (SCLC), usually using the same cytotoxic agents, jointly with surgery and radiotherapy, are discussed in the second part of this chapter.

Keywords

Non-small cell lung cancer Small-cell lung cancer Side effects Tyrosine kinase inhibitor (TKI) Platinum doublets Combined modalities 

References

  1. 1.
    Stewart B, Wild C, editors. World cancer report 2014. Lyon: International Agency for Research on Cancer; 2014.Google Scholar
  2. 2.
    Morgensztern D, Du L, Waqar SN, Patel A, Samson P, Devarakonda S, et al. Adjuvant chemotherapy for patients with T2N0M0 NSCLC. J Thorac Oncol. 2016;11:1729–35.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v1–v27.PubMedCrossRefGoogle Scholar
  4. 4.
    Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA. 2014;311:1430–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77.PubMedCrossRefGoogle Scholar
  6. 6.
    Soria JC, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917–29.PubMedCrossRefGoogle Scholar
  7. 7.
    Shaw AT, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–71.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Pujol JL, Barlesi F, Daures JP. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer. 2006;51:335–45.PubMedCrossRefGoogle Scholar
  9. 9.
    Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.PubMedCrossRefGoogle Scholar
  10. 10.
    NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617–25.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847–57.PubMedCrossRefGoogle Scholar
  12. 12.
    Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.PubMedCrossRefGoogle Scholar
  13. 13.
    Li M, Zhang Q, Fu P, Li P, Peng A, Zhang G, et al. Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. PLoS One. 2012;7:e37229.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24:20–30.PubMedCrossRefGoogle Scholar
  16. 16.
    Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:2895–902.PubMedCrossRefGoogle Scholar
  17. 17.
    Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13:247–55.PubMedCrossRefGoogle Scholar
  18. 18.
    Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16:763–74.PubMedCrossRefGoogle Scholar
  20. 20.
    Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Thatcher N, et al. 1320_PR: subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). J Thorac Oncol. 2016;11:S153.PubMedCrossRefGoogle Scholar
  21. 21.
    Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Rittmeyer A, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.PubMedCrossRefGoogle Scholar
  23. 23.
    Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–103.PubMedCrossRefGoogle Scholar
  24. 24.
    Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–97.PubMedCrossRefGoogle Scholar
  25. 25.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.PubMedCrossRefGoogle Scholar
  26. 26.
    Zhao N, Zhang XC, Yan HH, Yang JJ, Wu YL. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Lung Cancer. 2014;85:66–73.PubMedCrossRefGoogle Scholar
  27. 27.
    Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665–73.PubMedCrossRefGoogle Scholar
  28. 28.
    Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143–55.PubMedCrossRefGoogle Scholar
  29. 29.
    Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015;16:897–907.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, et al. 135O_PR: plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC. J Thorac Oncol. 2016;11:S154.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689–99.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17:234–42.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17:452–63.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Kim DW, et al. Brigatinib patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(22):2490–8.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577–89.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Mok T, et al. Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): a randomized, open-label phase III trial. J Clin Oncol. 2017;18(11):1454–66.Google Scholar
  38. 38.
    Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3342–50.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Geater SL, Xu CR, Zhou C, Hu CP, Feng J, Lu S, et al. Symptom and quality of life improvement in LUX-lung 6: an open-label phase III study of afatinib versus cisplatin/gemcitabine in Asian patients with EGFR mutation-positive advanced non-small-cell lung cancer. J Thorac Oncol. 2015;10:883–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Chen G, Feng J, Zhou C, Wu YL, Liu XQ, Wang C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol. 2013;24:1615–22.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26:1883–9.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Di Maio M, Leighl NB, Gallo C, Feld R, Ciardiello F, Butts C, et al. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. J Thorac Oncol. 2012;7:1830–44.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30:1122–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866–74.PubMedCrossRefGoogle Scholar
  46. 46.
    Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012;17:863–70.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079–95.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2016;5:CD010383.Google Scholar
  49. 49.
    Ramalingam SS, Shaw AT. Hypogonadism related to crizotinib therapy: implications for patient care. Cancer. 2012;118:E1–2.PubMedCrossRefGoogle Scholar
  50. 50.
    Felip E, et al. Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): whole body responses in the overall pt group and in pts with baseline brain metastases (BM). Ann Oncol. 2016;27:12080.CrossRefGoogle Scholar
  51. 51.
    Hida T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29–39.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Peters S, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–38.  https://doi.org/10.1056/NEJMoa1704795.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010;11:733–40.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Sandler A, Hirsh V, Reck M, von Pawel J, Akerley W, Johnson DH. An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. Lung Cancer. 2012;78:1–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Sclafani F, Giuseppe G, Mezynksi J, Collins C, Crown J. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer. J Clin Oncol. 2012;30:e257–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27:v119–v33.PubMedCrossRefGoogle Scholar
  57. 57.
    Azzoli CG, Kris MG, Pfister DG. Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed. J Natl Cancer Inst. 2007;99:828–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17:1141.PubMedCrossRefGoogle Scholar
  59. 59.
    Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994;12:1821–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Gridelli C, Cigolari S, Gallo C, Manzione L, Ianniello GP, Frontini L, et al. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the elderly study (MILES) randomized trial. Lung Cancer. 2001;31:277–84.PubMedCrossRefGoogle Scholar
  61. 61.
    Aapro MS, Martin C, Hatty S. Gemcitabine--a safety review. Anti-Cancer Drugs. 1998;9:191–201.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Barlesi F, Villani P, Doddoli C, Gimenez C, Kleisbauer JP. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol. 2004;18:85–91.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Roychowdhury DF, Cassidy CA, Peterson P, Arning M. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Investig New Drugs. 2002;20:311–5.CrossRefGoogle Scholar
  64. 64.
    Leal F, Macedo LT, Carvalheira JB. Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series. J Chemother. 2014;26:169–72.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer. 2004;43:183–94.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol. 1997;15:3149–55.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Reck M, Coon C, Taylor F, et al. Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017. Eur J Cancer. 2015;51:141.Google Scholar
  69. 69.
    Horn L, et al. Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous non-small cell lung cancer: subgroup analyses and patient reported outcomes. Ann Oncol. 2015;26:ix125.CrossRefGoogle Scholar
  70. 70.
    Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong AN, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2016;28(2):368–76.Google Scholar
  71. 71.
    Auperin A, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–90.PubMedCrossRefGoogle Scholar
  72. 72.
    Senan S, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34(9):953–62.PubMedCrossRefGoogle Scholar
  73. 73.
    Vokes EE, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: cancer and leukemia group B. J Clin Oncol. 2007;25(13):1698–704.PubMedCrossRefGoogle Scholar
  74. 74.
    Hanna N, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008;26(35):5755–60.PubMedCrossRefGoogle Scholar
  75. 75.
    Kelly K, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26(15):2450–6.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    PACIFIC trial. AstraZeneca press release. imfinzi significantly reduces the risk of disease worsening or death in the phase III PACIFIC trial for Stage III unresectable lung cancer; 2017.Google Scholar
  77. 77.
    Kates M, Swanson S, Wisnivesky JP. Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer<=1 cm in size: a review of SEER data. Chest. 2011;139:491–6.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Dai C, Shen J, Ren Y, Zhong S, Zheng H, He J, et al. Choice of surgical procedure for patients with non-small-cell lung cancer </= 1 cm or > 1 to 2 cm among lobectomy, segmentectomy, and wedge resection: a population-based study. J Clin Oncol. 2016;34:3175–82.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Cheung MC, Hamilton K, Sherman R, Byrne MM, Nguyen DM, Franceschi D, et al. Impact of teaching facility status and high-volume centers on outcomes for lung cancer resection: an examination of 13,469 surgical patients. Ann Surg Oncol. 2009;16:3–13.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Brunelli A, Refai M, Salati M, Xiume F, Sabbatini A. Predicted versus observed FEV1 and DLCO after major lung resection: a prospective evaluation at different postoperative periods. Ann Thorac Surg. 2007;83:1134–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Barnett SA, Rusch VW, Zheng J, Park BJ, Rizk NP, Plourde G, et al. Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases. J Thorac Oncol. 2011;6:1530–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Ferguson MK, Vigneswaran WT. Diffusing capacity predicts morbidity after lung resection in patients without obstructive lung disease. Ann Thorac Surg. 2008;85:1158–64. discussion 64-5PubMedCrossRefGoogle Scholar
  83. 83.
    Otake H, Yasunaga H, Horiguchi H, Matsutani N, Matsuda S, Ohe K. Impact of hospital volume on chest tube duration, length of stay, and mortality after lobectomy. Ann Thorac Surg. 2011;92:1069–74.PubMedCrossRefGoogle Scholar
  84. 84.
    Wahi R, McMurtrey MJ, DeCaro LF, Mountain CF, Ali MK, Smith TL, et al. Determinants of perioperative morbidity and mortality after pneumonectomy. Ann Thorac Surg. 1989;48:33–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Yan TD, Black D, Bannon PG, McCaughan BC. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. J Clin Oncol. 2009;27:2553–62.PubMedCrossRefGoogle Scholar
  86. 86.
    Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE, Landreneau RJ, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006;81:1013–9. discussion 9–20PubMedCrossRefGoogle Scholar
  87. 87.
    Saji H, Tsuboi M, Yoshida K, Kato Y, Nomura M, Matsubayashi J, et al. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer. J Thorac Oncol. 2011;6:1865–71.PubMedCrossRefGoogle Scholar
  88. 88.
    Pompili C, Brunelli A, Xiume F, Refai M, Salati M, Sabbatini A. Predictors of postoperative decline in quality of life after major lung resections. Eur J Cardiothorac Surg. 2011;39:732–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Moller A, Sartipy U. Predictors of postoperative quality of life after surgery for lung cancer. J Thorac Oncol. 2012;7:406–11.PubMedCrossRefGoogle Scholar
  90. 90.
    Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267–77.PubMedCrossRefGoogle Scholar
  91. 91.
    Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9.PubMedCrossRefGoogle Scholar
  92. 92.
    Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719–27.PubMedCrossRefGoogle Scholar
  93. 93.
    Wakelee HA. E1505: adjuvant chemotherapy +/- bevacizumab for early stage NSCLC—outcomes based on chemotherapy subsets. J Clin Oncol. 2016;34(suppl):8507.CrossRefGoogle Scholar
  94. 94.
    Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28:35–42.PubMedCrossRefGoogle Scholar
  95. 95.
    Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst. 2007;99:533–44.PubMedCrossRefGoogle Scholar
  96. 96.
    Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006;24:2998–3006.PubMedCrossRefGoogle Scholar
  97. 97.
    Burdett S, Rydzewska L, Tierney J, Fisher D, Parmar MK, Arriagada R, et al. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2016;9:CD002142.PubMedGoogle Scholar
  98. 98.
    Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–24.PubMedCrossRefGoogle Scholar
  99. 99.
    Arriagada R, Pignon JP, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients. Anticancer Res. 1994;14:333–5.PubMedGoogle Scholar
  100. 100.
    Pijls-Johannesma MC, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev. 2005;1:CD004700.Google Scholar
  101. 101.
    Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol. 2006;24:3823–30.PubMedCrossRefGoogle Scholar
  102. 102.
    Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20:3054–60.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–71.PubMedCrossRefGoogle Scholar
  104. 104.
    Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10:282–91.PubMedCrossRefGoogle Scholar
  105. 105.
    Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36–42.PubMedCrossRefGoogle Scholar
  106. 106.
    Pechoux CL, Sun A, Slotman BJ, De Ruysscher D, Belderbos J, Gore EM. Prophylactic cranial irradiation for patients with lung cancer. Lancet Oncol. 2016;17:e277–93.PubMedCrossRefGoogle Scholar
  107. 107.
    Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group. N Engl J Med. 1999;341:476–84.PubMedCrossRefGoogle Scholar
  108. 108.
    Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.PubMedCrossRefGoogle Scholar
  109. 109.
    Takahasi T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663–71.CrossRefGoogle Scholar
  110. 110.
    Wolfson AH, Bae K, Komaki R, Meyers C, Movsas B, Le Pechoux C, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81:77–84.PubMedCrossRefGoogle Scholar
  111. 111.
    Slotman BJ, Mauer ME, Bottomley A, Faivre-Finn C, Kramer GW, Rankin EM, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol. 2009;27:78–84.PubMedCrossRefGoogle Scholar
  112. 112.
    O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24:5441–7.PubMedCrossRefGoogle Scholar
  113. 113.
    Antonia SJ, Lopez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883–95.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of OncologyHFR FribourgFribourgSwitzerland

Personalised recommendations